EUVIMEDEUVIMED entdecken
Crossref

Identification of Artemisia Argyi (AA) Therapy in Alzheimer's Disease (AD) Using Network Pharmacology and Molecular Docking

Yin Wang, Ruixue Huang iD

Advanced Biology · 2023

DOI: 10.1002/adbi.202200256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Biology, 2023. Verfasst von Yin Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Occupational and Environmental Health, Xiangya School of Public Health, Central South University, Changsha, Hunan Province, 410078, Chi…. Hauptthemen laut MEDLINE: Alzheimer Disease, Molecular Docking Simulation, Artemisia, Network Pharmacology. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Research and Development (R&D) Plan of Hunan Province, Scientific research project of Hunan Health Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to investigate the molecular mechanism of Artemisia argyi (AA) in the treatment of cognitive impairment of Alzheimer's disease (AD) and the docking activity of AA on potential therapeutic targets using network pharmacology and molecular docking techniques. Bioinformatic analysis showed that neuroactive ligand‐receptor interaction, the pathway of cancer, calcium signaling, neurodegeneration‐multiple disease, and chemical carcinogenesis‐receptor activation might be the related signal pathway in AA‐AD. Moreover, the binding energy of AA active compounds to potential targets are ≦−4.16 kJ mol −1 with 10 patterns ≦−10 kJ mol −1 . The results of molecular docking showed that there would be a stable binding ability between the active components of AA and potential target genes. Among them, 24‐methylenecyloartanone, beta‐sitosterol, and Stigmasterol are active components with potential oral bioavailability (OB), drug‐likeness (DL), and blood‐brain‐barrier(BBB) are screened out with the stable binding ability to target genes, which may be potential components of AA treatment for AD. This study laid an important foundation for further study of the molecular mechanism of AA treatment for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMolecular Docking SimulationArtemisiaNetwork PharmacologyPlant ExtractsDrugs, Chinese HerbalHumans

Stichwörter der Autor:innen

Alzheimer's diseaseArtemisia argyidocking activityoral bioavailability

Substanzen

Plant ExtractsDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Department of Occupational and Environmental Health, Xiangya School of Public Health, Central South University, Changsha, Hunan Province, 410078, China.

ORCID-Profile: Ruixue Huang

Förderung

  • National Natural Science Foundation of China
  • Key Research and Development (R&D) Plan of Hunan Province
  • Scientific research project of Hunan Health Committee

Zitieren

APA

Wang, Y., & Huang, R. (2023). Identification of Artemisia Argyi (AA) Therapy in Alzheimer's Disease (AD) Using Network Pharmacology and Molecular Docking. Advanced Biology. https://doi.org/10.1002/adbi.202200256

Vancouver

Wang Y, Huang R. Identification of Artemisia Argyi (AA) Therapy in Alzheimer's Disease (AD) Using Network Pharmacology and Molecular Docking. Advanced Biology. 2023. doi:10.1002/adbi.202200256

BibTeX
@article{Wang2023,
  author = {Wang, Yin and Huang, Ruixue},
  title = {Identification of Artemisia Argyi (AA) Therapy in Alzheimer's Disease (AD) Using Network Pharmacology and Molecular Docking},
  journal = {Advanced Biology},
  year = {2023},
  doi = {10.1002/adbi.202200256}
}
Kostenlos starten →